Harmony Biosciences (NASDAQ:HRMY) CFO Sandip Kapadia Sells 3,746 Shares

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia sold 3,746 shares of Harmony Biosciences stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $37.15, for a total value of $139,163.90. Following the transaction, the chief financial officer owned 24,521 shares of the company’s stock, valued at $910,955.15. This represents a 13.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Sandip Kapadia also recently made the following trade(s):

• On Thursday, January 15th, Sandip Kapadia sold 20,961 shares of Harmony Biosciences stock. The shares were sold at an average price of $35.92, for a total value of $752,919.12.

Harmony Biosciences Trading Down 2.2%

HRMY stock opened at $36.84 on Thursday. Harmony Biosciences Holdings, Inc. has a one year low of $25.52 and a one year high of $40.87. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of 11.58, a price-to-earnings-growth ratio of 0.35 and a beta of 0.84. The company has a fifty day moving average price of $37.30 and a two-hundred day moving average price of $34.23. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.75 and a quick ratio of 3.72.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.05). Harmony Biosciences had a return on equity of 24.88% and a net margin of 22.50%.The company had revenue of $239.46 million for the quarter, compared to analyst estimates of $222.68 million. Equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

HRMY has been the topic of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $42.00 target price on shares of Harmony Biosciences in a research note on Monday, November 24th. Wall Street Zen upgraded Harmony Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Oppenheimer reissued an “outperform” rating and set a $62.00 target price on shares of Harmony Biosciences in a report on Monday, November 24th. HC Wainwright restated a “buy” rating on shares of Harmony Biosciences in a research note on Wednesday, December 3rd. Finally, Zacks Research upgraded shares of Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $45.25.

Institutional Trading of Harmony Biosciences

Several large investors have recently modified their holdings of HRMY. Amundi raised its stake in Harmony Biosciences by 115.6% in the first quarter. Amundi now owns 39,668 shares of the company’s stock valued at $1,229,000 after purchasing an additional 21,266 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Harmony Biosciences by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock valued at $752,000 after buying an additional 984 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Harmony Biosciences during the 1st quarter worth approximately $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Harmony Biosciences by 53.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock worth $3,166,000 after acquiring an additional 33,058 shares during the period. Finally, State of Alaska Department of Revenue boosted its position in shares of Harmony Biosciences by 8.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 22,897 shares of the company’s stock worth $722,000 after acquiring an additional 1,724 shares in the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.